"Lopinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D061466
|
| MeSH Number(s) |
D03.383.742.698.553
|
| Concept/Terms |
Lopinavir- Lopinavir
- N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
|
Below are MeSH descriptors whose meaning is more general than "Lopinavir".
Below are MeSH descriptors whose meaning is more specific than "Lopinavir".
This graph shows the total number of publications written about "Lopinavir" by people in this website by year, and whether "Lopinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 5 | 6 |
| 2012 | 4 | 2 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 4 | 4 | 8 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 1 | 5 | 6 |
| 2020 | 2 | 4 | 6 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lopinavir" by people in Profiles.
-
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360.
-
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infect Dis. 2022 May 12; 22(1):456.
-
Persistently lower bone mass and bone turnover among South African children living with well controlled HIV. AIDS. 2021 11 01; 35(13):2137-2147.
-
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021 08 16; 73(4):706-715.
-
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther. 2021 10; 110(4):1057-1065.
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.
-
The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec; 132:110829.
-
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine (Baltimore). 2020 Sep 11; 99(37):e21661.
-
Lopinavir-Ritonavir Impairs Adrenal Function in Infants. Clin Infect Dis. 2020 08 14; 71(4):1030-1039.
-
Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz. Bone. 2020 09; 138:115500.